checkAd

     189  0 Kommentare Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment - Seite 3

    Investor Contact:
    Michael Biega
    Senior Director, Investor Relations
    Sensei Biotherapeutics
    mbiega@senseibio.com

    Lesen Sie auch

    Media Contact:
    Joyce Allaire
    LifeSci Advisors
    Jallaire@lifesciadvisors.com


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment - Seite 3 BOSTON, April 04, 2024 (GLOBE NEWSWIRE) - Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the …